GlassScriptPhysician profile
David J Barney
NPI 1437254430
$20,530.57
in general payments reported to CMS, 2019-2025
54 companies · $4,425 in 2025
The $4,425 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,637 · 2022: $4,243 · 2023: $3,876 · 2024: $4,351 · 2025: $4,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,651.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,124.12 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,572.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,782.03 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,651.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $1,082.70 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,067.39 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Pfizer INC. | $889.60 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $774.48 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $770.75 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $633.72 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Lundbeck LLC | $449.45 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $408.84 | 2021-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $380.29 | 2021-2025 | |
| Amgen INC. | $361.22 | 2021-2025 | Evenity, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $352.65 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Barney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.